Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality of life and outcomes in stage IV non-small cell lung cancer
PACTR202104725647601Completed
- Sponsor
- Service de Pneumologie, Hôpital de la Croix-Rousse
- Start
- Feb 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vinorelbine, gemcitabine and docetaxel in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Service de Pneumologie, Hôpital de la Croix-Rousse. Primary endpoint: overall survival. Started Feb 2018; status: completed.
02
Drugs
vinorelbinegemcitabinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on PACTR202104725647601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202104725647601.